Evaluation of Heart Failure Treatment Guided by N-terminal Pro B-type Natriuretic Peptide (NTproBNP) vs Clinical Symptoms and Signs Alone

Summary

The purpose is to study if HF treatment guided by NTproBNP in addition to clinical symptoms and signs is more effective than treatment guided by clinical symptoms and signs alone in patients with HF and left ventricular systolic dysfunction

Conditions

• Heart Failure
• Ventricular Dysfunction, Left

Interventions

DRUG

Captopril

DRUG

Enalapril

DRUG

Lisinopril

DRUG

Ramipril

DRUG

Trandolapril

DRUG

Bisoprolol

DRUG

Carvedilol

DRUG

Metoprolol succinate

DRUG

Candesartan

DRUG

Valsartan

DRUG

Eplerenone

DRUG

Spironolactone

DRUG

Diuretics

DRUG

HF treatment according to Swedish guidelines

PROCEDURE

Blood samples

PROCEDURE

The Kansas City Cardiomyopathy Questionnaire (KCCQ)

Sponsors & Collaborators

• AstraZeneca

  lead INDUSTRY

Principal Investigators

• AstraZeneca Sweden Medical Director, MD · AstraZeneca

• Hans Persson, MD, PhD · Danderyd Hospital, Sweden

• Bjorn Eriksson, MD · AstraZeneca

Study Design

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

SINGLE

Model

PARALLEL

Eligibility

Min Age

18 Years

Sex

ALL

Healthy Volunteers

No

Timeline & Regulatory

Start

2006-10-31

Primary Completion

2009-01-31

Completion

2009-01-31

Countries

• Sweden

Study Locations